What is Allogene Therapeutics's interest coverage?

Allogene Therapeutics (ALLO) reported interest coverage of -155.3× in Q1 2026.

How has Allogene Therapeutics's interest coverage changed year-over-year?

Allogene Therapeutics's interest coverage increased by 80.9% year-over-year, from -812.3× to -155.3×.

What does interest coverage mean?

Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.

Allogene Therapeutics ALLO Interest coverage

Interest coverage at other companies

Gilead SciencesGILD

10.3×+2.0×

PrecigenPGEN

-22,521.4×-22,838×

Sana BiotechnologySANA

-65.2×-177×

Kyverna Therapeutics, Inc.KYTX

-144.7×-68.1×

Arcus BiosciencesRCUS

-39.8×-15.5×

OmerosOMER

-5.8×-1.2×

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Calculated from Allogene Therapeutics’s reported figures.

ebit/interest expense=-155.3×

Based on trailing twelve months.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's interest coverage?: Allogene Therapeutics (ALLO) reported interest coverage of -155.3× in Q1 2026.
How has Allogene Therapeutics's interest coverage changed year-over-year?: Allogene Therapeutics's interest coverage increased by 80.9% year-over-year, from -812.3× to -155.3×.
What does interest coverage mean?: Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.